Size | Price | Stock | Qty |
---|---|---|---|
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
TB5 is a novel, potent, selective, reversible and competitive inhibitor of hMAO-B (human monoamine oxidase-B) with Ki value of 0.11±0.01 μM. TB5 is can be potentially used for the treatment of neurodegenerative disorders like PD and AD (Parkinson's and Alzheimer's diseases). In addition, TB5 was found to be nontoxic at 5 and 25 μm, with 95.75% and 84.59 % viability among cells, respectively.
ln Vitro |
hMAO-B and hMAO-A's catalytic sites interact with TB5 and TB8 through a competitive method of inhibition. With Ki and SI values of 0.11±0.01μM and 13.18, compound TB5 exhibits the highest selectivity and best inhibitory action toward hMAO-B. After 24 hours of dialysis, the inhibition of hMAO-A by compound TB8 and hMAO-B by compound TB5 is totally reversed. According to cytotoxicity experiments, TB5 has no hazardous effects at 5 and 25 μM, meaning that 95.75% and 84.59% of cells can survive, respectively. [1].
|
||
---|---|---|---|
ln Vivo |
The compounds are diluted with PBS/EtOH (70:30) after being dissolved in DMSO (5 mg/mL). We do kinetic analyses on TB5 and TB8. A series of Lineweaver–Burk plots was created with and without different amounts of the chemicals TC8 and TB5. Each of the five graphs in the collection was created by calculating the catalytic rates of MAO-B and MAO-A at various substrate concentrations (0.1–1 μM). While the remaining four graphs are created with varying amounts of TB5 and TB8, the first Lineweaver–Burk plot is created without an inhibitor[1].
|
||
Animal Protocol |
|
||
References |
[1]. Mathew B, et al. Synthesis, Biochemistry, and Computational Studies of Brominated Thienyl Chalcones: A New Class of Reversible MAO-B Inhibitors. ChemMedChem. 2016 Jun 6;11(11):1161-71
|
Molecular Formula |
C15H14BRNOS
|
|
---|---|---|
Molecular Weight |
336.25
|
|
CAS # |
948841-07-4
|
|
SMILES |
O=C(C1=CC=C(Br)S1)/C=C/C2=CC=C(N(C)C)C=C2
|
|
Chemical Name |
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9740 mL | 14.8699 mL | 29.7398 mL | |
5 mM | 0.5948 mL | 2.9740 mL | 5.9480 mL | |
10 mM | 0.2974 mL | 1.4870 mL | 2.9740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.